Entera Bio Gains FDA Alignment For 12-Month Phase 3 Study Of EB613, First Oral Anabolic Tablet

Entera Bio Ltd. (ENTX) received positive FDA feedback on its planned 12-month registrational Phase 3 study of EB613, positioning the program for a potential New Drug Application based on one pivotal trial.